TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON ALPHA
- Evaluate the response and disease-free survival of patients with metastatic renal cell
carcinoma treated with subcutaneous interleukin-2 and interferon alfa.
- Assess the toxicity of this regimen.
OUTLINE: Patients undergo nephrectomy if the diseased kidney makes up the bulk of the tumor
All patients receive subcutaneous interferon alfa on day 1 and interleukin-2 on days 3-5 of
week 1, followed by reduced doses of interferon alfa and interleukin-2 on days 1, 3, and 5
of weeks 2-6. Patients are assessed for response approximately 2 months after initiating
therapy. Patients with stable or responding disease undergo a second course; those who
continue to respond may receive additional therapy provided toxicity is limited.
Patients are followed for survival.
PROJECTED ACCRUAL: 14 patients will be entered.
Primary Purpose: Treatment
Richard L. White, MD
Blumenthal Cancer Center at Carolinas Medical Center
United States: Federal Government
|Blumenthal Cancer Center at Carolinas Medical Center||Charlotte, North Carolina 28232-2861|